Key result
Low-dose corticosteroids improved the median percentage change in eGFR at 4 weeks compared to no steroids, but did not favorably affect long-term renal outcomes.
Why the study?
Does low-dose corticosteroid therapy improve short- and long-term renal outcomes in patients with cholesterol crystal embolism?
Cohort (n=51)
Does low-dose corticosteroid therapy improve short- and long-term renal outcomes in patients with cholesterol crystal embolism?
Low-dose corticosteroid therapy improves short-term renal function in patients with cholesterol crystal embolism but does not provide long-term renal benefits.
Answers are grounded in this paper and cite their sources.
Short-term eGFR gains with low-dose corticosteroids should not yet change practice; leaves open long-term renal benefit in cholesterol crystal embolism.
BACKGROUND: The effect of corticosteroids on renal cholesterol crystal embolism (CCE) remains uncertain. The aim of the present study was to elucidate the effect of steroid therapy on short- and long-term renal outcome in CCE patients. METHODS: Fifty-one patients diagnosed with renal CCE were included in this retrospective study. The patients were divided into two groups according to whether or not they had received steroid therapy (steroid therapy (+), n = 32; (-), n = 19). Corticosteroids were administered at an initial dose of 10-20 mg/day after CCE diagnosis. The values of the estimated glomerular filtration rate (eGFR) in the two groups were examined at CCE diagnosis, 4 weeks after diagnosis and the last follow-up. Additionally, the % change in eGFR at 4 weeks after diagnosis and % change per year in eGFR at the last follow-up were calculated for each patient. RESULTS: The median values of eGFR at diagnosis in patients with and without steroid therapy were 16.4 and 17.9 mL/min/1.73 m(2), respectively. The median % change in eGFR between diagnosis and 4 weeks after diagnosis was 24% in patients with steroid therapy and 5% in those without, and this difference was statistically significant. On the other hand, there was no significant difference between the two groups in the % change in eGFR per year between diagnosis and the last follow-up. CONCLUSIONS: During the short period after CCE diagnosis, steroid therapy showed a good renal outcome in CCE patients. However, this treatment did not have a favorable effect on long-term renal outcome.
No takes yet. Share an insight, caveat, or question.
Nakayama et al. (2011) conducted a cohort in renal cholesterol crystal embolism (CCE) (n=51). Corticosteroids vs. no steroid therapy was evaluated on median % change in eGFR between diagnosis and 4 weeks after diagnosis (p=statistically significant). Low-dose corticosteroids improved the median percentage change in eGFR at 4 weeks compared to no steroids, but did not favorably affect long-term renal outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: